1
|
Karachaliou CE, Liolios C, Triantis C, Zikos C, Samara P, Tsitsilonis OE, Kalbacher H, Voelter W, Papadopoulos M, Pirmettis I, Livaniou E. Specific in vitro binding of a new (99m)Tc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils. Int J Pharm 2015; 486:1-12. [PMID: 25796124 DOI: 10.1016/j.ijpharm.2015.03.031] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 03/13/2015] [Accepted: 03/16/2015] [Indexed: 11/28/2022]
Abstract
Prothymosin alpha (ProTα) is a conserved mammalian polypeptide with intracellular functions associated with cell proliferation and apoptosis and an extracellular role associated with immunopotentiation. The N-terminal fragment [1-28], which is identical with the immunostimulating peptide thymosin α1 (Tα1), was earlier considered as the immunoactive region of the polypeptide; however, recent data suggest that ProTα may exert a discrete immunomodulating action through its central or C-terminal region, via targeting Toll-like receptor- 4 (TLR4). In this work, a derivative of the C-terminal fragment ProTα[100-109] (ProTα-D1) that can be radiolabeled with (99m)Tc was developed. The biological activity of the non-radioactive (185/187)rhenium-complex of this derivative ([(185/187)Re]ProTα-D1, structurally similar with [(99m)Tc]ProTα-D1) was verified through suitable in vitro bioassays on human neutrophils. Subsequent cell-binding studies revealed specific, time-dependent and saturable binding of [(99m)Tc]ProTα-D1 on neutrophils, which was inhibited by intact ProTα and ProTα[100-109], as well as by a "prototype" TLR4-ligand (lipopolysaccharide from Escherichia coli). Overall, our results support the existence of ProTα-binding sites on human neutrophils, recognizing [(99m)Tc]ProTα-D1, which might involve TLR4. [(99m)Tc]ProTα-D1 may be a useful tool for conducting further in vitro and in vivo studies, aiming to elucidate the extracellular mode of action of ProTα and, eventually, develop ProTα-based immunotherapeutics.
Collapse
Affiliation(s)
- Chrysoula-Evangelia Karachaliou
- Institute of Nuclear and Radiological Sciences & Technology, Energy and Safety (INRaSTES), National Center for Scientific Research "Demokritos", Athens 15310, Greece
| | - Christos Liolios
- Institute of Nuclear and Radiological Sciences & Technology, Energy and Safety (INRaSTES), National Center for Scientific Research "Demokritos", Athens 15310, Greece
| | - Charalampos Triantis
- Institute of Nuclear and Radiological Sciences & Technology, Energy and Safety (INRaSTES), National Center for Scientific Research "Demokritos", Athens 15310, Greece
| | - Christos Zikos
- Institute of Nuclear and Radiological Sciences & Technology, Energy and Safety (INRaSTES), National Center for Scientific Research "Demokritos", Athens 15310, Greece
| | - Pinelopi Samara
- Faculty of Biology, University of Athens, Athens 15784, Greece
| | | | - Hubert Kalbacher
- Interfaculty Institute of Biochemistry, University of Tuebingen, Tuebingen 72076, Germany
| | - Wolfgang Voelter
- Interfaculty Institute of Biochemistry, University of Tuebingen, Tuebingen 72076, Germany
| | - Minas Papadopoulos
- Institute of Nuclear and Radiological Sciences & Technology, Energy and Safety (INRaSTES), National Center for Scientific Research "Demokritos", Athens 15310, Greece
| | - Ioannis Pirmettis
- Institute of Nuclear and Radiological Sciences & Technology, Energy and Safety (INRaSTES), National Center for Scientific Research "Demokritos", Athens 15310, Greece
| | - Evangelia Livaniou
- Institute of Nuclear and Radiological Sciences & Technology, Energy and Safety (INRaSTES), National Center for Scientific Research "Demokritos", Athens 15310, Greece.
| |
Collapse
|